# 156<sup>th</sup> Session of WHO Executive Board Meeting 3<sup>rd</sup> to 11<sup>th</sup> February 2025, Geneva



## Ministry of Health & Family Welfare Government of India

### **Intervention by India**

Agenda Item 7: Follow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases

#### Thank you chair,

India acknowledges the tabled agenda and appreciates the valuable insights shared on progress towards internationally agreed targets, particularly those related to the NCD Global Monitoring Framework, SDG Target 3.4, and global trends in NCD mortality.

We recognize the fact that Noncommunicable Diseases cause nearly three-quarters of deaths in the world. Every year 17 million people under the age of 70 die of NCDs, and 86% of them live in low- and middle-income countries.

These statistics serve as a solemn reminder of the urgent need for global collaboration to combat the NCDs including those associated with metabolic syndrome which not only threatens lives but also undermines health systems, economies, and the well-being of our societies.

#### Chair,

While acknowledging the importance of augmenting tertiary care services for major non-communicable diseases, India emphasizes the critical role of health promotion and prevention strategies, including lifestyle modifications, in effectively addressing the growing

burden of NCDs, particularly Nonalcoholic Fatty Liver Disease (NAFLD) and its associated risk factors.

Recognizing the significant global burden of NAFLD estimated to affect approximately one billion individuals worldwide, India advocates for a holistic approach to NCD prevention and control, with a particular focus on addressing the growing burden of metabolic syndrome that poses a substantial threat to public health.

#### Chair,

India reaffirms its commitment to achieving SDG 3.4 and creating resilient health systems and stands ready to collaborate with member states for NCDs management, particularly focusing on fatty liver diseases and metabolic syndrome.

#### Thank you!